Old Web
English
Sign In
Acemap
>
authorDetail
>
Rose Snipes
Rose Snipes
UCB
Medicine
Adverse effect
Immunology
Internal medicine
Tolerability
3
Papers
36
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
2020
Blood Advances
Tadeusz Robak
Maciej Kaźmierczak
Isidro Jarque
Vasile Musteaţă
Jacek Treliński
Nichola Cooper
Peter Kiessling
Ute Massow
Franz Woltering
Rose Snipes
Juan Ke
Grant Langdon
James B. Bussel
Stephen Jolles
Show All
Source
Cite
Save
Citations (21)
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
2019
Blood
Tadeusz Robak
Maciej Kaźmierczak
Isidro Jarque
Vasile Musteaţă
Jacek Treliński
Nichola Cooper
Peter Kiessling
Ute Massow
Franz Woltering
Rose Snipes
Juan Ke
Grant Langdon
Birgit Haier
James B. Bussel
Stephen Jolles
Show All
Source
Cite
Save
Citations (5)
Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis
2017
Blood
Tadeusz Robak
Isidro Jarque
Vasile Musteaţă
Peter Kiessling
Ute Massow
James Higginson
Rose Snipes
Stephen Jolles
Show All
Source
Cite
Save
Citations (10)
1